BPC-157 / TB-500 Refill 10mg — Product Identity & Format Specification
The BPC-157 / TB-500 Refill 10mg is a replacement cartridge for compatible AbsoluteBioLab dispensing pen devices, containing a lyophilised blend of two structurally and mechanistically distinct research peptides: BPC-157 (stable gastric pentadecapeptide, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) and TB-500 (synthetic analogue of the active fragment of thymosin beta-4, sequence Ac-LKKTETQ). Each refill cartridge contains a total nominal mass of 10 mg of the combined peptide blend, supplied as a lyophilised powder within a sealed cartridge. The refill format allows researchers to reload a compatible pen device without replacing the full pen body, supporting cost-effective and sustainable laboratory dispensing workflows.
| Attribute | BPC-157 Component | TB-500 Component |
|---|---|---|
| Full Name | Stable Gastric Pentadecapeptide BPC-157 | TB-500 (Thymosin Beta-4 Fragment Ac-LKKTETQ) |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Ac-Lys-Lys-Thr-Glu-Thr-Gln (heptapeptide) |
| CAS Number | 137525-51-0 | 77591-33-4 |
| Molecular Weight | 1419.5 g/mol | 887.0 g/mol |
| Molecular Formula | C62H98N16O22 | C38H68N10O14 |
| Origin | Synthetic; derived from human gastric juice protein BPC | Synthetic; derived from thymosin beta-4 (Tβ4) actin-binding domain |
| Pen Format Attribute | Value |
|---|---|
| Product Format | Replacement cartridge (lyophilised; compatible with AbsoluteBioLab pen devices) |
| Total Nominal Mass | 10 mg (combined BPC-157 + TB-500 blend) |
| Physical Form | Lyophilised powder within sealed cartridge |
| Salt Form | Acetate |
| Purity (HPLC) | ≥99.0% (each component verified independently) |
| Identity Confirmation | ESI-MS for each component; characteristic molecular ions confirmed |
| Endotoxin | <1 EU/mg |
| Dispensing Increment | Calibrated per batch; refer to batch CoA for volume-per-increment specification |
| Cartridge Capacity | Declared on batch label |
| Storage (pen, sealed) | −20 °C, desiccated, protected from light; stable ≥24 months from manufacture date |
| Storage (pen, in use) | 2–8 °C after first use; use within 30 days; do not freeze once reconstituted |
| Documentation | Batch-specific Certificate of Analysis (compound CoA + finished-format CoA) available on request |
| Intended Use | Controlled laboratory dispensing; in vitro and laboratory research only (RUO) |
Analytical Quality & Batch Documentation
Each batch of the BPC-157 / TB-500 Refill 10mg undergoes a two-tier analytical release process. Both peptide components are verified independently at the bulk compound stage before blending, and the finished pen format is subject to a separate quality release covering dispensing accuracy, cartridge integrity, and endotoxin testing. The compound-level Certificate of Analysis (CoA) documents HPLC purity chromatograms, ESI-MS spectra, and lot numbers for each component. The finished-format CoA documents the assembled pen batch, dispensing increment calibration, and endotoxin result.
| Test | Method | Specification | Stage |
|---|---|---|---|
| BPC-157 purity | RP-HPLC (C18, UV 220 nm) | ≥99.0% | Compound |
| TB-500 purity | RP-HPLC (C18, UV 220 nm) | ≥99.0% | Compound |
| BPC-157 identity | ESI-MS; MW 1419.5 g/mol | ±0.5 Da | Compound |
| TB-500 identity | ESI-MS; MW 887.0 g/mol | ±0.5 Da | Compound |
| Endotoxin | LAL (limulus amebocyte lysate) | <1 EU/mg | Finished format |
| Dispensing accuracy | Gravimetric calibration | Per batch specification | Finished format |
| Cartridge integrity | Visual + pressure test | No leakage; intact seal | Finished format |
| Water content | Karl Fischer titration | ≤5.0% | Compound |
Researchers should record the lot numbers from both CoA documents against experimental data to maintain full traceability from raw compound through to finished dispensing format. The dispensing increment specification on the batch CoA is essential for calculating the mass of blend delivered per actuation in quantitative research protocols.
Research Context: BPC-157 and TB-500 in the Scientific Literature
BPC-157 and TB-500 represent two distinct classes of tissue-active research peptides that have each accumulated substantial independent peer-reviewed literature. Their co-formulation in a single blend vial reflects the research interest in studying complementary mechanisms of extracellular matrix remodelling, cell migration, and angiogenesis within the same experimental system.
BPC-157: Pentadecapeptide Research Profile
BPC-157 (stable gastric pentadecapeptide) is a synthetic 15-amino acid sequence derived from the human gastric juice protein BPC. It has been studied extensively in rodent models of soft tissue injury, tendon repair, bone healing, and gastrointestinal mucosal integrity. Seiwerth et al. (2021) reviewed BPC-157’s role in wound healing and demonstrated its activity in counteracting bleeding disorders and promoting tissue repair across multiple organ systems, including skin, tendon, and gastrointestinal mucosa.[1] Mechanistically, BPC-157 has been reported to modulate the nitric oxide (NO) system, upregulate growth factor expression (VEGF, EGF), and promote angiogenesis through FAK-paxillin pathway activation.[2]
In tendon and ligament repair models, BPC-157 has been studied in the context of Achilles tendon transection, medial collateral ligament injury, and rotator cuff repair. Chang et al. (2011) demonstrated accelerated tendon-to-bone healing in a rat model following BPC-157 administration, with histological evidence of improved collagen fibre organisation and increased vascularity at the repair site.[3] A 2025 narrative review by McGuire et al. in Current Reviews in Musculoskeletal Medicine noted that BPC-157 engages multiple feedback mechanisms during wound healing and identified preliminary evidence for its activity in combination with thymosin beta-4 in knee injection models.[4]
TB-500: Thymosin Beta-4 Fragment Research Profile
TB-500 is a synthetic heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding domain of thymosin beta-4 (Tβ4), a 43-amino acid endogenous peptide produced by the thymus and platelets. Thymosin beta-4 functions as the primary actin-sequestering protein in mammalian cells, maintaining the pool of unpolymerised G-actin required for cytoskeletal dynamics, cell migration, and wound healing. Xing et al. (2021) reviewed the multifunctional regenerative properties of Tβ4, documenting its roles in promoting angiogenesis, tissue repair, and regeneration, and reducing scar formation across cardiac, dermal, and neurological injury models.[5]
Goldstein et al. (2012) characterised thymosin beta-4 as a multi-functional regenerative peptide with roles in the repair and regeneration of injured cells and tissues, noting that synthetic fragments retaining the LKKTETQ actin-binding motif preserve the cell migration-promoting activity of the full-length protein.[6] Hsieh et al. (2020) reported that TB-500 promoted tendon cell proliferation and migration in vitro and accelerated tendon repair in a rat Achilles tendon injury model, with upregulation of collagen type I and III expression.[7]
Complementary Mechanisms in the Research Literature
The scientific rationale for studying BPC-157 and TB-500 in combination derives from their mechanistically complementary profiles. BPC-157 primarily modulates angiogenic signalling, growth factor expression, and local tissue repair responses through the NO/VEGF axis, while TB-500 promotes cell migration and cytoskeletal reorganisation through actin-sequestration and LKKTETQ-mediated signalling. These pathways operate at different stages of the tissue repair cascade — BPC-157 acting predominantly on vascular and matrix remodelling, TB-500 on cell motility and actin dynamics — providing a rationale for their co-investigation in complex repair models. It should be noted that no peer-reviewed studies have formally characterised the pharmacodynamic interaction of BPC-157 and TB-500 as a co-formulated blend; researchers using this product should design experiments that account for the independent activities of each component.
“BPC 157 is effective in wound healing much like it is effective in counteracting bleeding disorders, produced by amputation, and/or anticoagulants application.”
All findings cited above were obtained in controlled laboratory or preclinical settings. The BPC-157 / TB-500 Refill 10mg supplied by AbsoluteBioLab is intended exclusively for in vitro and laboratory research use. It is not a medicinal product, has not been evaluated for safety or efficacy in humans, and is not intended for administration to humans or animals.
Refill Cartridge Format, Storage & Laboratory Handling
The BPC-157 / TB-500 Refill 10mg is supplied as a sealed replacement cartridge containing the lyophilised peptide blend. The cartridge is designed for use with compatible AbsoluteBioLab pen dispensing devices. Researchers should confirm cartridge compatibility with their pen device model before use; refer to the pen device documentation for installation instructions.
| Condition | Guidance |
|---|---|
| Sealed cartridge storage | −20 °C in a desiccated environment, protected from light; stable ≥24 months from manufacture date |
| Transport | Ambient temperature acceptable for short transit (<72 hours); cold-chain recommended for extended transit |
| Reconstitution solvent | Sterile water for injection (WFI) or bacteriostatic water; volume per batch CoA specification |
| In-use storage | 2–8 °C after first use; use within 30 days; do not freeze once reconstituted |
| Dispensing | Use calibrated dispensing increment per batch CoA; record actuation count for mass tracking |
| Compatibility | Compatible with standard aqueous research buffers; avoid high-temperature exposure after reconstitution |
| Device inspection | Inspect pen body and cartridge for physical damage before use; do not use if seal is compromised |
| Disposal | Dispose of pen and cartridge in accordance with local laboratory waste regulations for research peptides |
Researchers should handle the pen device in accordance with standard laboratory safety protocols for research-grade peptides. The refill cartridge is a single-use laboratory research component and must not be used outside its intended laboratory dispensing application. Personal protective equipment (gloves, lab coat, eye protection) is recommended during reconstitution and dispensing operations.
References
- Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard of Care. Biomedicines. 2021;9(7):792. PMC8275860
- Sikiric P, Rucman R, Turkovic B, et al. Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Current Pharmaceutical Design. 2018;24(18):1990–2001. PMID 34060823
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774–780. PMID 21130053
- McGuire FP, Martinez R, Lenz A, Skinner L, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine. 2025. doi:10.1007/s12178-025-09990-7
- Xing Y, Ye Y, Zuo H, Li Y. Progress on the Function and Application of Thymosin β4. Frontiers in Endocrinology. 2021;12:722294. PMC8724243
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37–51. PMID 22074294
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2020;98(3):373–384. PMID 32344448
Research Use Only — Legal Notice
The BPC-157 / TB-500 Blend 10mg Pen is supplied strictly for in vitro laboratory and research use only. This product is not a medicinal product, is not approved for human or veterinary use, and has not been evaluated by the Medicines and Healthcare products Regulatory Agency (MHRA) or any other regulatory authority for safety, efficacy, or quality as a therapeutic agent. It must not be administered to humans or animals. The pen format is a laboratory dispensing device and is not a medical device or injection pen. Purchase, possession, and use are subject to applicable UK and international regulations governing research chemicals. AbsoluteBioLab accepts no liability for misuse of this product outside its intended research application.
Reviews
There are no reviews yet.